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Abstract
Background: The MDM2 gene encodes a negative regulator of the p53 tumour suppressor
protein. A single nucleotide polymorphism (SNP) in the MDM2 promoter (a T to G exchange at
nucleotide 309) has been reported to produce accelerated tumour formation in individuals with
inherited p53 mutations. We have investigated the effect of the MDM2 SNP309 on clinical outcome
in a cohort of patients with germline mutations of BRCA1.
Methods: Genomic DNA was obtained for 102 healthy controls and 116 patients with established
pathogenic mutations of BRCA1 and Pyrosequencing technology™ was used to determine the
genotype at the MDM2 SNP309 locus.
Results: The polymorphism was present in 52.9% of the controls (G/T in 37.3% and G/G in 15.6%)
and 58.6% of the BRCA1 mutation carriers (47.4% G/T and 11.2% G/G). Incidence of malignancy
in female BRCA1 carriers was not significantly higher in SNP309 carriers than in wildtype (T/T)
individuals (72.7% vs. 75.6%, p = 1.00). Mean age of diagnosis of first breast cancer was 41.2 years
in the SNP309 G/G genotype carriers, 38.6 years in those with the SNP309 G/T genotype and 39.0
years in wildtype subjects (p = 0.80).
Conclusion: We found no evidence that the MDM2 SNP309 accelerates tumour development in
carriers of known pathogenic germline mutations of BRCA1.
Background
Inheritance of a truncating mutation of the breast cancer
predisposition gene BRCA1 has been reported to carry a
lifetime risk of breast cancer of between 50 and 80%, with
age at onset of first malignancy varying from the 2nd to the
8th  decade [1,2]. Clinical studies indicate that BRCA1
mutation carriers can benefit significantly from preventa-
tive surgery, with prophylactic oophorectomy reducing
breast cancer rates by up to 60% and ovarian cancer rates
by 95%, and prophylactic double mastectomy reducing
the incidence of breast cancer by up to 90% [3,4]. These
two interventions are however major surgical procedures
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with potentially significant psychological and medical
sequelae. The ability to predict whether a BRCA1 muta-
tion carrier is likely to develop malignant disease early or
late in life would facilitate the clinical management of
these patients.
No differences in penetrance have yet been documented
for different BRCA1 truncating mutations [2]. Inter-indi-
vidual variation in the speed at which BRCA1 mutation
carriers develop cancer is likely to be influenced by envi-
ronmental factors, but may also be affected by co-inherit-
ance of other disease modifying genes which interact with
the BRCA1 cellular pathway. The precise mechanisms by
which mutations in the BRCA1 gene result specifically in
breast and ovarian tumour growth remain to be eluci-
dated. It is however accepted that BRCA1, and BRCA2,
maintain genomic integrity through roles in transcrip-
tional regulation, homologous recombination and the
DNA damage response [5-7] and are required for the nor-
mal proliferative burst in early embryogenesis [8,9].
It has been noted that BRCA1 breast tumours have a
higher frequency of p53 mutations than sporadic breast
tumours and several lines of evidence now point to a role
for the tumour suppressor p53 in the development of
BRCA1 cancers [10-14]. Mice carrying homozygous muta-
tions of BRCA1 fail to develop beyond an early embryonic
stage but have their survival prolonged by the co-inherit-
ance of p53 mutations [15,16]. tBRCA1-/- mice carry a tar-
geted null mutation of BRCA1 restricted to the T-cell
lineage resulting in depletion of thymocytes and periph-
eral T-cells, and activation of p53 [17]. Thymocyte devel-
opment in these mice is restored in the absence of p53.
Such observations have led to the hypothesis that truncat-
ing mutations in BRCA1 lead to accumulation of DNA
damage and activation of cell cycle checkpoints including
activation of p53, with the subsequent suggestion that dis-
ruption of the p53 pathway may be required before a
BRCA1 mutation results in tumour development [7].
The co-inheritance of alterations in the p53 tumour sup-
pressor pathway would therefore be expected to modify
the clinical affects of a BRCA1 mutation. Pre-clinical stud-
ies by McPherson et al. have provided evidence of the role
Chk2 plays in mediating accumulation and activation of
p53 in BRCA1 deficient mice [18]. A deficiency of Chk2
partially rescued the defective development and growth of
BRCA1 deficient T-cells but enhanced tumour develop-
ment. Recently Bond et al, (2004) have reported a single
nucleotide polymorphism (SNP) within the MDM2 gene
that can result in a partially attenuated p53 response and
accelerated tumour development in carriers [19].
MDM2 encodes a protein which directly binds to and
inhibits p53 [20] but also has p53 independent negative
effects on DNA double strand break repair [21,22].
MDM2 gene amplification is found in a number of
tumour types, including sporadic breast cancers, [23] and
overexpression of MDM2 is associated with accelerated
tumour development and failure to respond to treatment
[24]. Bond et al, (2004) have described a T to G exchange
at nucleotide 309 within the promoter region of MDM2,
which increases the affinity of the transcriptional activator
Sp1 and results in higher levels of MDM2 protein with
subsequent attenuation of the p53 tumour suppression
pathway [19]. Their study of 88 individuals with inherited
p53 mutations demonstrated that carriers of this SNP in
either its' homozygous or heterozygous form developed
cancer on average 7 years before their wildtype counter-
parts. Additionally, individuals homozygous for SNP309
but with no known hereditary cancer predisposition
showed a significantly earlier age of onset of sporadic soft
tissue sarcoma than those with the T/T genotype.
Given the evidence for interaction between the p53 stress
response and the BRCA1 cellular pathway, MDM2 could
be a plausible disease modifying gene in BRCA1 mutation
carriers. We have therefore investigated the effect of the
MDM2 SNP309 on clinical outcome in a cohort of
patients with germline mutations of BRCA1 with estab-
lished pathogenic potential.
Methods
Subjects
Potential study participants with previously diagnosed
truncating mutations of BRCA1 were identified from the
database of the Wessex Clinical Genetics Service (WCGS),
Southampton. Genomic DNA was obtained for 116
BRCA1 mutation carriers, 20 male and 96 female. Age at
time of screening for BRCA1 mutations ranged between
29 and 57 years. The clinical histories of all subjects were
reviewed to ascertain age at first and subsequent malig-
nancies. Fifty-nine gene carriers had developed breast can-
cer and a further 14 had ovarian cancer. Ten patients had
undergone prophylactic bilateral oophorectomy (five
after developing breast cancer) and 3 patients had under-
gone bilateral risk reducing mastectomy. All malignancies
occurred in female subjects; male subjects were therefore
excluded from all analyses of cancer incidence. 102 anon-
ymous genomic DNA samples, (46 male, 56 female, age
range 16–82) referred by WCGS for genetic screening of
non-neoplastic conditions, were obtained to provide an
unmatched control group. All research was performed
with the approval of the South West Hampshire Local
Research Ethics Committee (study reference numbers: 05/
Q1702/154 and MREC98/5/27).
Genotyping
Genotyping was performed using Pyrosequencing™ tech-
nology. Amplicons were generated in a 50 µl reaction vol-BMC Cancer 2006, 6:80 http://www.biomedcentral.com/1471-2407/6/80
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ume with 15 pmol each of MDM2F (5'
GTCTCCGCGGGAGTTCA 3') and MDM2R (5' Biotin –
GACTACGCGCAGCGT TCAC 3'), 0.2 mM dNTPs, 1.5
mM MgCl2, 1X Buffer II (Applied Biosystems), 1U Ampli-
Taq Gold (Applied Biosystems) using 10 ng genomic
DNA. PCR conditions were 94°C for 7 min; 50 cycles with
denaturation at 94°C for 30s, annealing at 60°C for 30s
and elongation at 72°C for 30s; 1 cycle at 72°C for 7 min;
and a final hold at 15°C. Thermocycling was performed
using a PTC-0225 DNA Engine Tetrad (MJ Research).
Single-stranded biotinylated PCR products were prepared
for Pyrosequencing using a Vacuum Prep Tool (Biotage
AB). 3 µl Streptavidin Sepharose™ HP (Amersham) was
added to 37 µl Binding buffer (10 mM Tris-HCl pH 7.6, 2
M NaCl, 1 mM EDTA, 0.1% Tween 20) and mixed with 20
µl PCR product and 20 µl high purity water for 10 min at
room temperature using a Variomag Monoshaker (Cam-
lab). The beads containing the immobilised templates
were captured onto the filter probes after applying the vac-
uum and then washed with 70% ethanol for 5 sec, dena-
turation solution (0.2 M NaOH) for 5 sec and washing
buffer (10 mM Tris-Acetate pH 7.6) for 5 sec. The vacuum
was switched off and the beads released into a PSQ 96
well plate containing 45 µl annealing buffer (20 mM Tris-
Acetate, 2 mM MgAc2 pH 7.6), 0.3 µM MDM2 sequencing
primer (5'GGGCTGCGGGGCCGCT 3'). The samples
were heated to 80°C for 2 min and then allowed to cool
to room temperature.
Pyrosequencing reactions were performed according to
the manufacturer's instructions using the PSQ 96 SNP
Reagent Kit (Biotage AB) which contained the enzyme
and substrate mixture and nucleotides. Assays were per-
formed using the nucleotide dispensation order
AGTACGCGC. The sample genotype was determined
using SNP Software (Biotage AB).
Statistical Analysis
Comparisons of frequencies were analysed using Fisher's
Exact for 3 × 2 contingency tables. A one way ANOVA was
used to compare age of onset of malignancies. All statisti-
cal calculations were performed using StatXact™ version 5
or Minitab™ statistical analysis software as appropriate.
Results
The heterozygous form of SNP309 (G/T) was present in
38 of the 102 controls (37.3%) with the homozygous
form present in 16 (15.6%). This distribution was not sig-
nificantly different from that within the BRCA1 mutation
carriers: 13 /116 (11.2%) were G/G, 55 /116 (47.4%)
were G/T and 48/116 (41.4%) were T/T, (p = 0.286).
Seventy-one of the 96 female BRCA1 mutation carriers
had been diagnosed with at least one malignancy of any
histological type (table 1). The incidence of malignancy
was highest in G/G genotype carriers with these patients
developing tumours in 10/12 cases (83.3.%). G/T carriers
developed tumours in 30/43 cases (69.8%) and wildtype
(T/T) individuals developed tumours in 31/41 cases
(75.6%), but statistical analysis revealed no significant
association between incidence of malignancy and geno-
type (p = 0.61).
Breast cancer had developed in 59 of the females with
BRCA1 mutations: 5/12 (41.7%) of those with the G/G
genotype, 27/43 (62.8%) of those with the G/T genotype
and 27/ 41 (65.8%) of those with the T/T genotype. Mean
age of diagnosis of first breast cancer did not vary signifi-
cantly with genotype, being 41.2 years (range 29–49) in
Table 1: Incidence and age of onset of all malignancies, breast and ovarian cancer in carriers of pathogenic BRCA1 mutations 
genotyped for MDM2 SNP309 (p values refer to comparisons of frequencies between the G/G, G/T and T/T subgroups)
Genotype (female subjects only) Total 
n = 96
G/G 
n = 12
G/T 
n = 43
T/T 
n = 41
Number of subjects with ≥1 malignancy (%) 71 (74.0%) 10 (83.3%) 30 (69.8%) 31 (75.6%) p = 0.61
No. of subjects with breast cancer (%) 59 (61.5%) 5 (41.7%) 27 (62.8%) 27 (65.8%) p = 0.34
Mean age of onset of 1st breast cancer/years 
(range)
41.6 (26–57) 41.2 (29–49) 38.6 (29–52) 39.0 (26–57) p = 0.80
No. of subjects with ovarian cancer (%) 14 (14.6%) 4 (33.3%) 4 (9.3%) 6 (14.6%) p = 0.32
Mean age of onset of 1st ovarian cancer/years 
(range)
58.0 (44–74) 62.3 (51–74) 60.3 (51–68) 53.7 (44–66) p = 0.32
Other malignancies 3 1 plasmacytoma 1 cervical cancer 1 uterine cancer
No. of patients undergoing prophylactic bilateral 
oophorectomy
10 0 5 5
No. of patients undergoing bilateral risk reducing 
mastectomy
31 1 1BMC Cancer 2006, 6:80 http://www.biomedcentral.com/1471-2407/6/80
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the SNP309 G/G carriers, 38.6 years (range 29–52) in SNP
G/T carriers, and 39.0 years (range 26–57) in subjects with
the wildtype genotype (p = 0.80) (figure 1).
Ovarian cancers occurred in 14 females: 4 with G/G geno-
type (33.3%), 4 with G/T (9.3%) and 6 with T/T (14.6%,
p = 0.32). Mean age of onset was similar in each genotype
group being 62.3 years in the G/G group (range 51–74),
60.3 years in the G/T group (range 51–68 years) and 53.7
years in the wildtype group (range 44–66), p = 0.32.
Discussion
Analysis of our control group of 102 confirmed that the
MDM2 SNP309 genetic variation is relatively common
within the general population with a frequency of 37.3%
for the heterozygous state (G/T) and 15.6% for the
homozygous state (G/G). Our figure for the homozygous
frequency is slightly higher than that reported by Bond et
al, (2004) in their analysis of 50 healthy volunteers (40%
G/T, 12% G/G) but is similar to that found by Campbell
et al. in another control group from the UK [19,25]. We
have shown that distribution of this polymorphism
within carriers of pathogenic BRCA1 mutations is not sig-
nificantly different from that within the general popula-
tion.
Our group of 116 BRCA1 mutation carriers had developed
a significant number of malignancies (total incidence
61.2%) but our work has shown no evidence of a signifi-
cant association between genotype at MDM2 nucleotide
309 and incidence of breast or ovarian cancer in female
subjects. There is however a non-significant trend for
increased incidence of all malignancies and of ovarian
cancer in the G/G genotype group. The incidence of malig-
nancy is so high in each group that it would be difficult to
observe a statistically significant difference between sub-
groups in this size study population. The number of sub-
jects in this study was limited by availability of BRCA1
mutation positive DNA within the Wessex Clinical Genet-
ics Service; extension of this study to additional regional
genetics services would increase its statistical power. A
recent study by Campbell et al. found no significant asso-
ciation between the G/G genotype and breast cancer in a
group of 218 early onset breast cancer patients (age at
onset of less than 40 years) or in a group of 248 patients
with familial breast cancer (defined as two or more cases
of breast cancer reported in first or second-degree relatives
or bilateral breast cancer) [25]. The BRCA1 mutation sta-
tus of Campbell's subjects was however not reported.
It should be noted that the mean age at time of BRCA1
testing for the G/G patients is significantly higher than
that of the G/T and T/T groups at 58.7 years, compared
with 49.9 years for G/T carriers and 48.9 years for wildtype
patients (p = 0.034). The G/G group therefore have had
longer to develop malignancies than the other subjects. In
addition, 5 patients in each of the G/T and T/T groups had
undergone prophylactic oophorectomy whilst no patients
with the G/G genotype had had this procedure. This may
have affected the incidence of ovarian cancers in the G/T
and T/T groups and could also have reduced the frequency
of breast cancers in the 5 subjects (4 G/T, 1 T/T) who had
not already developed this disease. The trend for increased
incidence of ovarian cancers in the G/G group does per-
haps warrant further study in a larger cohort of patients
who have not undergone prophylactic surgery.
Of most interest is the fact that we found no association
between SNP309 genotype and age of onset of breast can-
cer in female subjects with pathogenic BRCA1 mutations.
Pre-clinical studies have shown clear evidence of an inter-
action between the p53 tumour suppressor and BRCA1
cellular pathways. It could therefore be expected that par-
tial attenuation of the p53 pathway associated with the
MDM2 SNP309, as described by Bond et al. would have
exacerbated the effect of the BRCA1 mutation in promot-
ing early onset breast cancer [19]. Our results may indicate
that the increased MDM2 levels associated with the
SNP309 are insufficient to attenuate response in the
BRCA1 mutant breast cells, whereas in the Li Fraumeni
cohort studied by Bond et al, there is already loss of one
p53 allele. Alternatively, the transcription factors influ-
enced by SNP309 could be cell type specific so that this
polymorphism does not affect MDM2 expression in
breast and ovarian tissue. MDM2 amplification has in fact
been reported to be rare in ovarian cancers regardless of
p53 mutation status, suggesting that this gene may not be
significantly involved in the development of these
tumours [26]. Overexpression of MDM2 has however
been found in up to 73% of breast cancers [23] and breast
Scatter plot of age of onset of first breast cancer in carriers  of pathogenic BRCA1 mutations genotyped for MDM2  SNP309 Figure 1
Scatter plot of age of onset of first breast cancer in carriers 
of pathogenic BRCA1 mutations genotyped for MDM2 
SNP309.
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cancers comprised 17 out of 66 of the tumours reported
by Bond's cohort of Li Fraumeni individuals [19].
P53 mutations are the most commonly found genetic
alteration in human tumours and a number of studies
have reported a higher frequency of p53 mutations in
BRCA1 associated breast tumours and ovarian cancers
than sporadic breast/ ovarian cancers [11,13,15,27]. The
p53 status of breast cancers occurring in our subjects is
however currently unknown and it is therefore possible
that an association between accelerated tumour develop-
ment and MDM2 SNP309 would be found if analyses
were restricted to BRCA1 mutation carriers with evidence
of associated p53 protein abnormalities in the breast
tumour.
Our results are consistent with those of Campbell et al.
who found no evidence that the G/G genotype accelerated
breast cancer development in 147 patients with a positive
family history of this malignancy or bilateral breast can-
cer, a proportion of whom are likely to carry BRCA1 muta-
tions [25]. Bond et al, (2004) found clear evidence of
accelerated tumour development in 88 individuals carry-
ing germline mutations of p53 and in 105 soft tissue sar-
coma patients with no known familial tendency. More
recently, this group have commented on the disparity in
the difference in mean age of disease onset between the G/
G and T/T groups of sporadic sarcomas (12 years) and the
difference in median age of disease onset (21 years). These
figures arise as a result of a few G/G individuals develop-
ing cancer at a later age comparable with the wildtype
individuals. Bond et al, have attributed these findings to
the existence of additional genetic modifiers [28]. Alhop-
uro et al, have now published a study in which no statisti-
cally significant association between SNP309 genotype
and patient age at disease onset was found in cohorts of
early uterine leiomyosarcoma (68 subjects), colorectal
cancer (1042 subjects) or squamous cell head and neck
cancer (162 subjects) [29]. These results together with our
own findings suggest that the influence of the MDM2
SNP309 on tumour development is specific to certain
patient subgroups.
Conclusion
We have found no evidence that the presence of the
MDM2 SNP 309 accelerates tumour development in carri-
ers of known pathogenic germline mutations of BRCA1.
This polymorphism seems unlikely to act as a significant
disease modifier in this population.
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